India’s small pharma units are at a crossroads. As the country pushes to align its drug manufacturing standards with global benchmarks under the revised Schedule M, thousands of micro and small enterprises are struggling to keep up. What was intended as a quality upgrade for the sector is now...
India’s pharmaceutical industry, valued at US$ 55 billion in FY 2023-24, is rapidly emerging as a global healthcare powerhouse. With projections to reach US$ 130 billion by 2030 and an aspirational US$ 450 billion by 2047, the sector is set to nearly double its global market share to 5%. Already...
U.S. President Trump’s “Most Favoured Nation” (MFN) pricing policy seeks to lower prescription drug costs by ensuring the U.S. pays no more than the lowest price worldwide. This could pressure countries like India, a major producer of affordable generics, to raise drug prices — potentially undermining the global competitiveness of...
India’s CRDMO industry is poised for significant growth, with its market size expected to double from US$ 7 billion to US$ 14 billion by 2028, driven by a 14% CAGR, reveals a report by Macquarie Equity Research. Increasing pharmaceutical outsourcing, regulatory support, and global supply chain shifts favor India’s position...
Director General of Foreign Trade Santosh Kumar Sarangi has said that India’s ambitious target of reaching a US$ 2 trillion trade economy is “not unachievable”. Speaking at the first India Business and Trade Conclave here in New Delhi, the DGFT listed out industries where India’s exports can outshine and also...
Post-COVID-19, India needs to strengthen its pharma R&D ecosystem to tap into emerging drug development opportunities, particularly in the realm of infectious diseases. As the global R&D ecosystem moves towards a more collaborative approach and possibly accelerated new drug development cycles, India needs to reorient its pharma industry to become...
Dr. DK Srivastava, Chief Policy Advisor, EY India, proposes a three-phase roadmap for the public sector and private sector to strengthen India’s manufacturing prowess in line with evolving technologies and changing global trends. IBT: What are the major factorat make India’s attractiveness as a manufacturing destination most compelling in the...
Sanjay Singh, Partner – Deal Advisory, Head of Lifesciences, KPMG in India, identifies new generics opportunities, established manufacturing ecosystem, growing penetration of health insurance and talent pool as some of the key growth drivers for the Indian pharmaceutical industry over the next decade. IBT: The government is planning to come...
Though a new guideline released by the General Office of the State Council, China has revised the registration and approval of pharmaceutical products to fasten the process, the implementation still needs a lot of work. China has exempted import tariffs for 28 drugs, including all cancer drugs, from 1st May...
India Business & Trade is a thought leadership initiative of the Trade Promotion Council of India, a premier trade promotion body recognised by the Department of Commerce, Government of India.
India Business & Trade
M-62, Saket, New Delhi-110064, India
Stay ahead in the dynamic world of trade and commerce with India Business & Trade’s weekly newsletter.
Copyright © 2026 India Business & Trade. All Rights Reserved
